Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02354859 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)
A Phase 2 study, sponsored by University of Washington.
- Completed
- Registry status
- Phase 2
- Development phase
- 119
- Enrollment target
NCT02354859 is a Phase 2 study that has completed, run by University of Washington. The registered enrollment target is 119 participants.
The verdict
NCT02354859, a Phase 2 study, has completed, sponsored by University of Washington.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 119 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy of IV gallium to improve pulmonary function as measured by a 5% or greater relative improvement in forced expiratory volume in one second (FEV1) from baseline to Day 28. Funding Source - FDA OOPD
Interventions
- DRUG Normal Saline
- DRUG Gallium nitrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 119 participants |
| Start Date | 2016-03 |
| Est. Completion | 2018-02-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02354859
The ClinicalTrials.gov registry entry for NCT02354859 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 119 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Normal Saline is the first listed.
NCT02354859 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02354859 about?
NCT02354859 is a clinical study titled "A Phase 2 IV Gallium Study for Patients With Cystic Fibrosis (IGNITE Study)". The purpose of this study is to assess the efficacy of IV gallium to improve pulmonary function as measured by a 5% or greater relative improvement in forced expiratory volume in one second (FEV1) from baseline to Day 28. Funding Source - FDA OOPD
What is the current status of trial NCT02354859?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 119 participants. The study started on 2016-03. Estimated completion is 2018-02-01.
What interventions are being tested in trial NCT02354859?
The interventions under investigation include: Normal Saline (DRUG), Gallium nitrate (DRUG).
Who is sponsoring clinical trial NCT02354859?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.